Juno Therapeutics (JUNO) Tops Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Juno Therapeutics (JUNO) PT Raised to $60 at Cowen
November 3, 2017 6:02 AM EDTCowen raised its price target on Juno Therapeutics (NASDAQ: JUNO) to $60.00 (from $49.00) while maintaining an Outperform rating.
Analyst Chris Shibutani believes robust efficacy, safety and durability data for JCAR017 in DLBCL from more patients at ASH can further bolster confidence in Junos competitive... More
UPDATE: SunTrust Robinson Humphrey Upgrades Juno Therapeutics (JUNO) to Buy, Potential Takeout Target
November 2, 2017 6:48 AM EDT(Updated - November 2, 2017 7:52 AM EDT)
(updated to expand analyst comment)
SunTrust Robinson Humphrey upgraded Juno Therapeutics (NASDAQ: JUNO) from Hold to Buy with a price target of $65.00 (from $25.00).
Analyst Peter Lawson likes the company's best-in-class safety and efficacy... More
Juno Therapeutics (JUNO) PT Raised to $64 at Wedbush
November 2, 2017 6:43 AM EDTWedbush analyst David Nierengarten raised his price target on Juno Therapeutics (NASDAQ: JUNO) to $64.00 (from $42.00) while maintaining an Outperform rating after the ASH update shows 6mo response rates with JCAR017 in TRANSCEND at high dose are superior to that achieved with competing CAR-Ts (comparing... More
